Real-world Outcomes and Predictive Biomarkers for 177Lutetium Prostate-specific Membrane Antigen Ligand Treatment in Metastatic Castration-resistant Prostate Cancer: A European Association of Urology Young Academic Urologists Prostate Cancer Working Group Multi-institutional Observational Study

Autor: Kafka, Mona, Horninger, Andreas, di Santo, Gianpaolo, Virgolini, Irene, Neuwirt, Hannes, Unterrainer, Lena M., Kunte, Sophie C., Deiss, Emil, Paffenholz, Pia, Heidenreich, Axel, Rasul, Sazan, Einspieler, Holger, Shariat, Shahrokh F., Rajwa, Pawel, Dozauer, Robert, Tsaur, Igor, Medlock, Ellen, Rölz, Niklas, Rausch, Steffen, la Fougère, Christian, Trautwein, Nils, Roesch, Marie C., Merseburger, Axel S., Zattoni, Fabio, Sepulcri, Matteo, Ladurner, Michael, Bektic, Jasmin, Gandaglia, Giorgio, Horninger, Wolfgang, Heidegger, Isabel
Zdroj: European Urology Oncology; 20230101, Issue: Preprints
Abstrakt: 177Lu-labeled prostate-specific membrane antigen radioligand therapy is a highly effective treatment option in metastatic castration-resistant prostate cancer. A prostate-specific antigen decrease of ≥30% after the first two cycles and lower alkaline phosphatase (≤220 U/l) and gamma-glutamyl transferase (≤31 U/l) levels before therapy are parameters predictive for treatment success in patients without visceral metastases.
Databáze: Supplemental Index
Externí odkaz: